Table 1.
Clinical data, laboratory, and histological findings of IgAN patients at time of diagnosis and last follow-up.
| IgAN | Healthy Controls | |
|---|---|---|
| n | 61 | 55 |
| Age (years) (Median, range) | 41.2 (20–66.8) | 43.2 (20.5–64) |
| Gender (female), n(%) | 24 (39.34%) | 22 (40%) |
| eGFR (CKD-EPI) (ml/min/1.73 m2) (M ± SD) | 60.9 ± 24.6 | n.d. |
| Uprot (mg/24 h) (M ± SD) | 1.7 ± 0.9 | n.d. |
| Microhematouria (mH) n(%) | 60 (98.36%) | n.d. |
| Macrohematuria (MH) n(%) | 15 (24.59%) | n.d. |
| SBP (mmHg) (M ± SD) | 145 ± 12 | 125 ± 10 |
| DBP (mmHg) (M ± SD) | 98 ± 5 | 85 ± 4 |
| Renal Biopsy | ||
| M0/M1 | 9/52 | - |
| E0/E1 | 45/16 | - |
| S0/S1 | 20/41 | - |
| T0/T1/T2 | 43/16/2 | - |
| C0/C1/C2 | 47/12/2 | - |
| End of follow-up | ||
| Follow-up (years) (median, range) | 11.9 (0.7–25.1) | n.d. |
| eGFR (CKD-EPI) (ml/min/1.73 m2) (M ± SD) | 41.27 ± 30.3 | n.d. |
| Uprot (mg/24 h) (M ± SD) | 1.08 ± 0.9 | n.d. |
| ≥50% eGFR reduction + ESRD n(%) | 29 (47.54%) | n.d. |
| Annual change of eGFR (M ± SD) | −2.9 ± 5.1 | n.d. |
| SP/MP/FP | 15/24/22 | n.d. |
Abbreviations: IgAN: IgA Nephropathy, eGFR: estimated Glomerular Filtration Rate, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure. CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration, M ± SD: Mean ± Standard Deviation, SP: Slow Progressors, MP: Moderate Progressors, FP: Fast Pogressors, n.d.: not defined.